Epidermal growth factor receptor (EGFR) mutations were strongly correlated with the clinical benefit of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) and the first druggable driver mutation in non-small-cell lung cancer (NSCLC) 1,2. Here, EGFR is linked to non-small cell lung carcinoma.